Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma.

Dichloromethylene diphosphonate (Cl2MDP), an inhibitor of oestoclast activity, was evaluated for its ability to decrease the excessive mobilization of skeletal calcium that complicates multiple myeloma. Ten patients with active myeloma, wide-spread bone disease, and hypercalciuria were studied in a double-blind, placebo-controlled, crossover-designed trial in which they took Cl2MDP for eight weeks and placebos for eight weeks. Two patients died during the placebo phase; of eight patients who received Cl2MDP, seven had rapid, sustained, and highly significant (P less than 0.001) decreases in urinary excretion of calcium. Six also had significant decreases in hydroxyproline excretion, and five reported lessening of skeletal pain. On patient did not respond. Although the patients received concurrent chemotherapy during the study, concentrations of myeloma proteins actually increased or decreased only slightly, indicating the declines in hypercalciuria resulted from Cl2MDP and not from improvement in the underlying disease. We conclude that Cl2MDP is a potentially useful inhibitor of osteoclast-mediated bone erosion in multiple myeloma.

[1]  H. Fleisch,et al.  Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats , 1973, Calcified Tissue Research.

[2]  E. Vignon,et al.  EFFECTS OF DISODIUM DICHLOROMETHYLENE DIPHOSPHONATE ON PAGET'S DISEASE OF BONE , 1979, The Lancet.

[3]  J. Zerwekh,et al.  Treatment of calcium urolithiasis with diphosphonate: efficacy and hazards. , 1979, The Journal of urology.

[4]  O. Bijvoet,et al.  INHIBITION OF OSTEOLYTIC BONE LESIONS BY (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (A.P.D.) , 1979, The Lancet.

[5]  L.,et al.  TREATMENT OF PAGET'S DISEASE WITH (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (A.P.D.) , 1979, The Lancet.

[6]  G. Mundy,et al.  Direct resorption of bone by human breast cancer cells in vitro , 1978, Nature.

[7]  L. Raisz,et al.  Comparison of the effects of stimulators and inhibitors of resorption on the release of lysosomal enzymes and radioactive calcium from fetal bone in organ culture. , 1978, Endocrinology.

[8]  R. Luben.  Purification of a lymphokine: osteoclast activating factor from human tonsil lymphocytes. , 1978, Biochemical and biophysical research communications.

[9]  H. DeLuca,et al.  Response of 1alpha,25-dihydroxyvitamin D3 to hypocalcemia in human subjects. , 1978, The New England journal of medicine.

[10]  H. Koeffler,et al.  Production of bone resorbing activity in poorly differentiated monocytic malignancy , 1978, Cancer.

[11]  A. Broadus,et al.  Nephrogenous cyclic adenosine monophosphate as a parathyroid function test. , 1977, The Journal of clinical investigation.

[12]  L. Raisz.  Bone Metabolism and Calcium Regulation , 1977 .

[13]  R. Canfield,et al.  Diphosphonate therapy of paget's disease of bone. , 1977, The Journal of clinical endocrinology and metabolism.

[14]  P. Saville,et al.  Etidronate disodium in postmenopausal osteoporosis , 1976, Clinical pharmacology and therapeutics.

[15]  C. Galasko.  Mechanisms of bone destruction in the development of skeletal metastases , 1976, Nature.

[16]  S. L. Stover,et al.  Disodium etidronate in the prevention of heterotopic ossification following spinal cord injury (preliminary report) , 1976, Paraplegia.

[17]  P. Kelly,et al.  Multiple-myeloma bone disease. The comparative effect of sodium fluoride and calcium carbonate or placebo. , 1975, The New England journal of medicine.

[18]  J. Oates,et al.  Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. , 1975, The New England journal of medicine.

[19]  H. Fleisch,et al.  Quantitative determination of ethane-1-hydroxy-1,1-diphosphonate in urine and plasma. , 1975, Clinica chimica acta; international journal of clinical chemistry.

[20]  H. Fleisch,et al.  Pyrophosphate and diphosphonates in skeletal metabolism. Physiological, clinical and therapeutic aspects. , 1975, Clinical orthopaedics and related research.

[21]  P. Walker,et al.  TREATMENT OF OSTEOLYTIC MYELOMATOSIS WITH MITHRAMYCIN , 1975, The Lancet.

[22]  R. Kyle.  Multiple myeloma: review of 869 cases. , 1975, Mayo Clinic proceedings.

[23]  G. Mundy,et al.  Evidence for the secretion of an osteoclast stimulating factor in myeloma. , 1974, The New England journal of medicine.

[24]  C. Pak,et al.  The hypercalciurias. Causes, parathyroid functions, and diagnostic criteria. , 1974, The Journal of clinical investigation.

[25]  S. Wallach,et al.  Response of Paget's disease to porcine and salmon calcitonins: effects of long-term treatment. , 1974, The American journal of medicine.

[26]  R. Altman,et al.  Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). , 1973, The New England journal of medicine.

[27]  E. Osserman,et al.  The treatment of multiple myeloma. , 1973, Seminars in hematology.

[28]  J. Harley,et al.  Ineffectiveness of fluoride therapy in multiple myeloma. , 1972, The New England journal of medicine.

[29]  R. Russell,et al.  Treatment of myositis ossificans progressiva with a diphosphonate. , 1972, Lancet.

[30]  B. Riggs,et al.  Immunologic differentiation of primary hyperparathyroidism from hyperparathyroidism due to nonparathyroid cancer. , 1971, The Journal of clinical investigation.

[31]  W. R. King,et al.  Effect of disodium ethane-1-hydroxy-1, 1-diphosphonate on bone formation. , 1971, Clinical orthopaedics and related research.

[32]  H. Fleisch,et al.  Isolation of inorganic pyrophosphate from bovine and human teeth. , 1968, Archives of oral biology.

[33]  K. Kivirikko,et al.  Modifications of a specific assay for hydroxyproline in urine. , 1967, Analytical biochemistry.

[34]  J. Potts,et al.  Production of parathyroid hormone by nonparthyroid tumors. , 1967, Journal of Clinical Endocrinology and Metabolism.

[35]  K. Takatsuki,et al.  MULTIPLE MYELOMA I. THE PATHOGENESIS OF "AMYLOIDOSIS. , 1964, Seminars in hematology.